These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 10996633)

  • 41. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy for prostate cancer.
    Fong L; Small EJ
    Semin Oncol; 2003 Oct; 30(5):649-58. PubMed ID: 14571412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The potential for prostate cancer immunotherapy.
    Rini BI; Small EJ
    Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S117-25. PubMed ID: 12850532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
    Schadendorf D; Paschen A; Sun Y
    Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dendritic cell-based immunotherapy for prostate cancer.
    Jähnisch H; Füssel S; Kiessling A; Wehner R; Zastrow S; Bachmann M; Rieber EP; Wirth MP; Schmitz M
    Clin Dev Immunol; 2010; 2010():517493. PubMed ID: 21076523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in Therapeutic Cancer Vaccines.
    Wong KK; Li WA; Mooney DJ; Dranoff G
    Adv Immunol; 2016; 130():191-249. PubMed ID: 26923002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic vaccines for prostate cancer: a review of clinical data.
    Arlen PM; Gulley JL
    Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dendritic cell vaccination of patients with metastatic colorectal cancer.
    Burgdorf SK
    Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).
    Harzstark AL; Small EJ
    Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dendritic cells and T cells in immunotherapy.
    O'Neill DW
    J Drugs Dermatol; 2010 Nov; 9(11):1383-92. PubMed ID: 21061761
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens.
    Turkeri L; Onol FF; Ozyurek M
    Urol Oncol; 2010; 28(3):290-5. PubMed ID: 19362861
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
    Reardon DA; Mitchell DA
    Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Dendritic cell-based cancer vaccine].
    Burgdorf SK; Claësson MH; Rosenberg J
    Ugeskr Laeger; 2006 Apr; 168(14):1420-3. PubMed ID: 16584669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.